Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets. - Wikidata - awgldk - TriplyDB

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.

http://www.wikidata.org/entity/Q37650735

about

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy Reactive Oxygen Species-Mediated Mechanisms of Action of Targeted Cancer Therapy Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens.Three-dimensional microtissues essentially contribute to preclinical validations of therapeutic targets in breast cancer.Epidermal growth factor receptor imaging in human head and neck cancer xenografts.Immunological low-dose radiation modulates the pediatric medulloblastoma antigens and enhances antibody-dependent cellular cytotoxicity.Meeting Report From the Prostate Cancer Foundation Scientific Working Group on Radium-223.

P2860

Q26797345-D828F0B0-DD70-4DB6-8D47-A0A31795BB4F Q33862425-DB4806B7-1801-4E2E-A1E0-EE0C563BF128 Q33878572-D9942A40-139C-4937-A820-E3D8ADF0BE70 Q36797292-11211640-6FD0-4AFB-AA45-16E842293382 Q38561772-D292914C-EDAB-4F06-ACAC-322645D0300E Q38726656-5AE5CDBF-4713-4314-B0F5-672F677956D4 Q38995718-0A69079C-A35A-4912-8B60-BC09AF174DD9

P2860

Expanding the use of monoclonal antibody therapy of cancer by using ionising radiation to upregulate antibody targets.

http://www.wikidata.org/entity/Q37650735

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 20 February 2014

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Expanding the use of monoclona ...... o upregulate antibody targets.

@en

Expanding the use of monoclona ...... o upregulate antibody targets.

@nl

type

label

Expanding the use of monoclona ...... o upregulate antibody targets.

@en

Expanding the use of monoclona ...... o upregulate antibody targets.

@nl

prefLabel

Expanding the use of monoclona ...... o upregulate antibody targets.

@en

Expanding the use of monoclona ...... o upregulate antibody targets.

@nl

P1433

Q37650735-9E51738D-F299-4BEC-95EA-EF52F4D716F2

P1476

Q37650735-07C00D04-5341-4573-8A06-1C0B43C81FAD

P2093

Q37650735-64D69D23-D9A3-4114-B152-760FE824E4AF

Q37650735-6F77FA82-5B22-4097-A491-CE8AEEBFE347

Q37650735-9BBCA5A2-E093-4B23-A70F-15C59186CF69

P2860

Q37650735-019DC9B8-8E2E-4292-AC5A-EAC4EE862378

Q37650735-140F019C-635B-450D-BF4E-2D8E71BE730A

Q37650735-15B75E94-EB8C-40BA-B761-6608713EBE3A

Q37650735-23CB5BAA-0AD5-4DF1-A1CF-99C5122091D6

Q37650735-29B717D4-594E-47B3-BE77-A1DDE397F044

Q37650735-3020625A-C778-4CA5-90D8-726AF3F5A5E5

Q37650735-3B03614A-2623-4684-A91F-20F2908896A5

Q37650735-3F5098A8-728C-44F3-96BF-10B6277CEAB2

Q37650735-40BE89D9-310F-48F6-9C67-646608EDE69B

Q37650735-41A06C6B-14F6-4EDF-B7A8-B48A375CDCEB

P2888

Q37650735-618AEF99-484A-4754-A5D3-D5ABA514265D

P304

Q37650735-3489ACCA-F527-4D0C-9E9A-D597D695D92D

P31

Q37650735-72925C6F-E23E-43F7-B0C0-D869E6785259

P356

Q37650735-F149CEAB-3AFD-4D84-B1E7-C9B8203206D6

P407

Q37650735-D1CEA2D3-F524-41D2-8550-76D1D7BEC23A

P433

Q37650735-C121C2A7-E359-4F55-8586-F11E27FE0ABA

P478

Q37650735-4CF97C47-9BDD-4909-8430-11432B217BC2

P50

Q37650735-1C19676D-1E83-4BF1-B6DC-4161F16BED84

Q37650735-40708D24-54F0-4492-93D9-A3A3EC017D08

P577

Q37650735-691DB323-93D2-48B5-BA11-E4E5E26B3A79

P5875

Q37650735-CD4D7001-1925-4FDD-AEA2-8DDF461EE2A1

P698

Q37650735-DAAC913E-4DED-4741-A90C-71ACBC2AD102

P921

Q37650735-02D1B5E4-93E4-4CD3-B98B-448A5F46309F

Q37650735-0BDF3438-592A-4B30-AFA8-3B6F27B604E0

P932

Q37650735-FEEB6475-1316-4C85-A9A6-D4F0FFC86F87

P356

P1433

British Journal of Cancer

P1476

Expanding the use of monoclona ...... to upregulate antibody targets

@en

P2093

A R Kwilas

http://www.w3.org/2001/XMLSchema#string

J W Hodge

http://www.w3.org/2001/XMLSchema#string

M M Wattenberg

http://www.w3.org/2001/XMLSchema#string

P2860

NIH Image to ImageJ: 25 years of image analysis

Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941

Current role of EGF receptor monoclonal antibodies and tyrosine kinase inhibitors in the management of head and neck squamous cell carcinoma

Combining radiotherapy and cancer immunotherapy: a paradigm shift

The response of CD24(-/low)/CD44+ breast cancer-initiating cells to radiation

NF-kappaB-mediated HER2 overexpression in radiation-adaptive resistance.

Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment.

Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited.

Development of Herceptin resistance in breast cancer cells.

Impact of Rituximab (Rituxan) on the Treatment of B-Cell Non-Hodgkin's Lymphoma.

P2888

P304

1472-1480

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1038/BJC.2014.79

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

110

http://www.w3.org/2001/XMLSchema#string

P50

Sofia R Gameiro

P577

2014-02-20T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260370826

http://www.w3.org/2001/XMLSchema#string

P698

24556625

http://www.w3.org/2001/XMLSchema#string

P921

radiation therapy

P932

3960628

http://www.w3.org/2001/XMLSchema#string